@misc{indiciae33dd2203c4ec,
  title = {primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.},
  author = {Alexander Cj van Akkooi and Michal Kicinski and Anne-Sophie Govaerts and Axel Hauschild and Piotr Rutkowski and Petr Arenberger and Paolo A Ascierto and Piotr Tomczak and Ga\&\#xeb;lle Quereux and Federica De Galitiis and Caroline Dutriaux and Christoffer Gebhardt and Ellen Kapiteijn and Laurent Machet and Miguel Ga Berciano and Michele Del Vecchio and Mathilde Jalving and Thomas Jouary and Ivana Krajsova and Suzana Matkovic and Barbara Merelli and Laurent Mortier and Pages-LaurentCecile Pag\&\#xe8;s-Laurent and Giuseppe Palmieri and Marc Pracht and Yvetta Vantuchova and Daniela Massi and Nathalie Elaut and Gaetan de Schaetzen and Sarah Nuyens and Nitish Jha and Isabelle Klauck and Beno\&\#xee;t Sansas and Jean Claude Vedovato and Paul C Lorigan and Georgina V Long and Alexander Mm Eggermont and Mario Mandala},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116951},
  url = {https://pubmed.ncbi.nlm.nih.gov/42501621/},
  note = {Source identifier: 42501621}
}